Founded by Hermann Lubbert, Biofrontera is a leading force in healthcare innovation, with a keen focus on the development of drugs and medicinal cosmetics for the treatment of skin diseases and regeneration of damaged skin. Leveraging technology and scientific research, Biofrontera pioneers an important breakthrough in the healthcare sector, proving to be a remarkable innovation in dermatological treatment. Based in Leverkusen, Nordrhein-Westfalen, Germany, the company is a testament to Germany’s fast-paced healthcare startup landscape.
Biofrontera’s standout product, Ameluz®, was developed for the treatment of actinic keratosis and is now marketed across several European countries. Fueled by a potent source of red light, Ameluz® is an integral part of Photodynamic Therapy, a procedure bolstered by the company’s specially created BF-RhodoLED® lamp. Approved by the US FDA and CE in Europe, this medical solution places Biofrontera at the forefront of dermatological advancements.
- Key Takeaways:
- Biofrontera specializes in the treatment of skin diseases and skin regeneration.
- The company’s drug, Ameluz®, is used in Photodynamic Therapy to treat actinic keratosis.
- Biofrontera developed the BF-RhodoLED® lamp for effective Photodynamic Therapy.
- The company also markets a cosmeceutical product, Belixos® creme, for the care of inflamed and reddened skin.
- Biofrontera plans to expand its cosmeceutical product range under the Belixos brand.
What sets Biofrontera apart in the bustling healthcare startup scene is its multisided approach to dermatological treatment. Not only does the firm develop pharmaceutical solutions but they also delve into the realm of medicinal cosmetics. Their cosmeceutical product, Belixos® creme, is designed for the regenerative care of inflamed and reddened skin, and the firm aims to roll out a full line of cosmeceutical products under the Belixos brand soon. Overall, Biofrontera preserves a well-rounded perspective on skincare and dermatology, innovative in their approach and comprehensive in their remedies.
A significant contributing factor to Biofrontera’s distinction lies in its organizational structure and strategic partnerships. The Biofrontera Group consists of the parent company and five wholly owned direct subsidiaries. This structuring allows them to efficiently meet the diverse needs of their operations, from research and development to licensing and marketing. It also enables the necessary separations to ensure appropriate financing for innovative projects beyond Biofrontera’s core business.
With continuous advancements in the healthcare industry, Biofrontera is poised to lead in dermatological solutions and skin regeneration treatment. Their cutting-edge photodynamic therapy and cosmeceutical efforts exemplify a revolutionary trend in the field. As they continue to develop and introduce innovative solutions to the market, the potential for significant, even life-changing impacts on dermatological patients is very promising.
For more information on Biofrontera and their work in revolutionizing dermatological treatment, visit their website at http://www.biofrontera.com. You can also follow them on their social media platforms for updates on their latest developments.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
